NTII Neurobiological Technologies (MM)

EMERYVILLE, Calif., May 2 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII), today announced it has received approximately $1,900,000 from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease for the quarter ended December 31, 2006. Under an exclusive marketing agreement, NTI receives quarterly royalty payments on sales of Memantine by Merz and its marketing partners. Paul E. Freiman, President and CEO of Neurobiological Technologies said, "This once again is the largest single royalty payment received to date from Merz, up $200,000 from the last quarter. This is a positive reflection of the marketing performed by Merz's partners, Forest Laboratories and H Lundbeck A/S. These payments continue to aid us in the funding of our Viprinex (TM) (ancrod) Phase III clinical program investigating the treatment of acute ischemic stroke within a six hour time window." About Neurobiological Technologies, Inc. NTI is a drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company's strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. We anticipate that we will continue to acquire and develop late-stage neurologic drug candidates and will develop the resources to market these drugs in selected world regions. Our goal is to develop and market drug candidates in the United States, Europe and Asia, and we may seek partnerships with pharmaceutical and biotechnology companies to assist us. For additional information, please visit our website at http://www.ntii.com/. Note regarding forward-looking statements: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our reliance on Merz and its marketing partners, our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, the risks associated with the cost of clinical development efforts, risks associated with patient enrollment in clinical trials, and other risks detailed from time to time in our Securities and Exchange Commission filings. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We disclaim, however, any intent to update these forward-looking statements. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Craig W. Carlson, VP & CFO of Neurobiological Technologies, Inc., +1-510-595-6000 Web site: http://www.ntii.com/

Copyright